Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026065 · ClinicalTrials.gov registry record · Phase 1
Hypertension: Prediction of Biofeedback Success
A Phase 1 study of Essential Hypertension, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00026065: Completed Phase 1 study of Essential Hypertension, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00026065 is a Phase 1 study of Essential Hypertension that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 60 participants, below the 796-participant average among 8 other Essential Hypertension trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026065, a Phase 1 study of Essential Hypertension, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypertension, present in more than 50 million Americans, increases the risk of cardiovascular disease and its associated complications. More persons are turning to alternative medicine to deal with their health problems. Biofeedback may reduce blood pressure and/or allow the reduction of antihypertensive medications in some patients, while having no adverse effects. Yet biofeedback therapy is time-intensive and technician-intensive. Therefore, it is critical to be able to predict which patients with essential hypertension are most likely to lower his/her blood pressure using these techniques. This research proposes to test three different means of predicting whether a hypertensive subject will or will not be successful in lowering his/her blood pressure using biofeedback. Sixty hypertensive subjects will be studied over a three-year period. The results of this study will enable those caring for hypertensive persons to recommend biofeedback in an individualized way, thereby promoting adherence.
Conditions Studied
Interventions
- BEHAVIORAL Biofeedback
Study Locations (1)
Florida
- University of Florida College of Nursing - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2000-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
What the finished NCT00026065 record still lists
NCT00026065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 796-participant average among 8 other Essential Hypertension trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Biofeedback is the first listed.
NCT00026065 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00026065 about?
NCT00026065 is a clinical study titled "Hypertension: Prediction of Biofeedback Success". Hypertension, present in more than 50 million Americans, increases the risk of cardiovascular disease and its associated complications. More persons are turning to alternative medicine to deal with their health problems. Biofeedback may reduce blood pressure and/or allow the reduction of antihyperte...
What is the current status of trial NCT00026065?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2000-02. Estimated completion is 2006-03.
What conditions does trial NCT00026065 study?
This clinical trial studies the following conditions: Essential Hypertension.
What interventions are being tested in trial NCT00026065?
The interventions under investigation include: Biofeedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT00026065?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026065 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00026065's enrollment target sits among peer trials
60 7th of 8 higher than 2 of 8 other Essential Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Essential Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
ACTIVE NOT RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
COMPLETED · NA
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia